Physician profile
Thomas Rastle
NPI 1972522506
$2,644.41
in general payments reported to CMS, 2019-2025
27 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $357 · 2021: $337 · 2022: $146 · 2023: $186 · 2024: $181 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $786.08 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $238.04 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $188.57 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $179.30 | 2019-2025 | |
| Si-Bone, INC. | $146.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $122.27 | 2019-2020 | |
| Lilly USA, LLC | $119.31 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Sanofi-Aventis U.S. LLC | $118.81 | 2019-2023 | |
| Amgen INC. | $91.08 | 2019-2025 | Evenity |
| Acclarent, INC | $90.08 | 2019 | |
| Merck Sharp & Dohme LLC | $72.41 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $61.13 | 2019-2022 | |
| Boston Scientific Corporation | $54.89 | 2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $49.72 | 2022-2023 | Freestyle Libre 2, Octrode |
| E.R. Squibb & Sons, L.L.C. | $48.47 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $45.55 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.32 | 2019-2020 | |
| Dexcom, INC. | $35.04 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $27.94 | 2025 | |
| Sanofi Pasteur INC. | $25.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.83 | 2019 | |
| Amarin Pharma, INC. | $17.13 | 2019 | |
| Bioventus LLC | $15.14 | 2022 | |
| Medtronic USA, INC. | $15.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.50 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2020 | |
| Biowound Solutions, INC. | $9.84 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rastle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.